Merck & Company Inc (MRK)vsOncternal Therapeutics Inc (ONCT)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
ONCT
Oncternal Therapeutics Inc
$0.53
0.00%
HEALTHCARE · Cap: $1.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3080372% more annual revenue ($66.57B vs $2.16M). MRK leads profitability with a 4.8% profit margin vs 0.0%. ONCT earns a higher WallStSmart Score of 43/100 (D).
MRK
Hold36
out of 100
Grade: F
ONCT
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+78.6%
Fair Value
$2.46
Current Price
$0.53
$1.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Revenue surging 176.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : ONCT
The strongest argument for ONCT centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 176.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : ONCT
The primary concerns for ONCT are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while ONCT is a hypergrowth play — different risk/reward profiles.
ONCT carries more volatility with a beta of 1.33 — expect wider price swings.
ONCT is growing revenue faster at 176.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
ONCT scores higher overall (43/100 vs 36/100) and 176.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Oncternal Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of cancer therapies for cancers with critical unmet medical needs. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?